Document is current
Any future updates will be listed below
-
Authors
Beckman, Madeline https://orcid.org/0000-0002-0283-8902
Srivastava, Sunil K.
Lowder, Careen Y.
Baynes, Kim
Lowe, Ashley
Sharma, Sumit https://orcid.org/0000-0001-5769-0717
- License Information
-
More Information
Article History
Received: 3 March 2025
Revised: 24 August 2025
Accepted: 25 September 2025
First Online: 6 November 2025
Competing interests
: SS reports consulting fees from 4DMT, Alimera, AbbVie, Apellis, Astellas, Bausch and Lomb, Clearside, Eyepoint, Harrow, Genetech/Roche, Kodiak, Merck, Regeneron, RegenXBio, Ripple, Volk, and Zeiss, with contracted research support from Acelyrin, Gilead, Genetech/Roche, Santen, IONIS, Kodiak. SKS reports grants from Regeneron, Eyevensys, Eyepoint, and Gilead, and consulting fees from Adverum, Novartis, Zeiss, and Bausch and Lomb.
